Procedure for Administration of Non-formulary Depot Atypical (New-Generation) Antipsychotic Medications on 7th Floor Psychiatry

1) It is expected that the atypical depot injections will not be initiated during a stay on 7th floor Psychiatry, but only be provided as continuation of current outpatient treatment. The most likely scenario would be patients who are currently in the CHCS patient roster. Given the nature of the mental illnesses for which these medications are used to treat, most will already have a specified CHCS case manager. The Case manager will be contacted by the ordering faculty psychiatrist, and informed of need for medication continuation. The CHCS case manager will bring the medication to the 7th floor inpatient faculty psychiatrist who will be ordering within the UH Sunrise/EMR system.

NB: Although it is fully anticipated that the vast majority will be CHCS patients, should the rare need arise for another clinic’s patient to receive depot medication, the same general policy would apply

2) Although not initiated during inpatient 7th floor Psychiatry stay, medication dosing adjustments may occur. This would be communicated to CHCS by the attending psychiatrist from the 7th floor during the initial notification/request for medication (see above).

3) Broader, current UHS Home-medication-for-inpatient-administration policy covers the medications themselves. However, the currently available New-Generation depot meds to be administered to patients while inpatient on 7th floor psychiatry, namely

- Invega (paliperidone) Sustenna
- Zyprexa (olanzapine) Relprevv, and
- Abilify (aripiprazole) Maintena

carry some unique properties from a procedural standpoint.

Due to the nature of the medications, marked expense, and patient populations, and billing peculiarities, these medications will be delivered by CHCS (whose staff would be administering them in CHCS clinics) Case Managers directly to the 7th floor psychiatry unit to the attending psychiatrist of record. The attending psychiatrist will provide the med vials/packages to the pharmacy for verification per UH pharmacy policy. Upon verification, the physician will place the order in the EMR (Sunrise) for the medication to be given per dosing instructions for each.

NOTES:

a. Invega Sustenna instructions are straight forward for dosing in gluteal deep IM injection
b. Abilify Maintena is also gluteal IM injection.

c. Zyprexa Relprevv:
   i. The attending physician and the 7th floor Psychiatry service (site) will both be registered per FDA/Lilly requirements.
   ii. The post-dosing 3-hour monitoring period required by FDA/Lilly will be done per 7th floor Nursing SOP. (See Attachments)
   iii. Should Adverse Events (AEs) occur the Attending physician will report the AEs to the pharmacy per ADR protocol as well as the (online) Lilly Relprevv procedure.

4) Should the patient be discharged prior to medication administration, the medication will be retrieved from 7th floor Psychiatry by CHCS Case Manager for administration in the regular CHCS clinic.

Prepared by: Christopher Wallace, MD
Approved by P&T: May 2013